Oxidative stress and smoking-induced vascular injury

Progress in Cardiovascular Diseases

Volumn 46, Issue 1, 2003, Pages 79-90

  Burke, Anne ^b   FitzGerald, Garret A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; BIOLOGICAL MARKER; CIGARETTE SMOKE; FREE RADICAL; LIPOPROTEIN; NICOTINE; REACTIVE OXYGEN METABOLITE;

ADRENERGIC SYSTEM; ARTERY ENDOTHELIUM; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL ACTIVATION; CLINICAL TRIAL; CONCENTRATION RESPONSE; CORRELATION ANALYSIS; DISEASE PREDISPOSITION; DNA DETERMINATION; HEMOSTASIS; HUMAN; LIPID METABOLISM; LIPID PEROXIDATION; MEASUREMENT; NONHUMAN; OXIDATIVE STRESS; PASSIVE SMOKING; PATHOGENESIS; PROTEIN STRUCTURE; QUANTITATIVE ANALYSIS; RELIABILITY; REVIEW; RISK FACTOR; SMOKING HABIT; THROMBOGENESIS;

EID: 0042467754     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0033-0620(03)00076-8     Document Type: Article

References (121)

1. Oxidative stress: adaptation, damage, repair and death, in Halliwell B, Gutteridge JMC, eds. Free Radicals in Biology and Medicine. Oxford: Oxford University Press, 1999, pp 346-350
2. Griendling KK, FitzGerald GA: Oxidative stress and vascular injury. Circulation 2003 (in press)
3. Church DF, Pryor WA: Free radical chemistry of cigarette smoke and its toxicological implications. Environ Health Perspect 64:111, 1985
4. Detection of free radicals and other reactive species: Trapping and fingerprinting, in Halliwell B, Gutteridge JMC, eds. Free Radicals in Biology and Medicine. Oxford: Oxford University Press, 1999, pp 351-429
5. Esposti MD: Measuring mitochondrial reactive oxygen species. Methods 26:335-340, 2002
6. Tarpey MM, Fridovich I: Methods of detection of vascular reactive species: Nitric oxide, superoxide, hydrogen peroxide, and peroxynitrite. Circ Res 89:224-236, 2001
7. Meagher EA, FitzGerald GA: Indices of lipid peroxidation in vivo: Strengths and limitations. Free Radic Biol Med 28:1745-1750, 2000
8. Hecker M, Haurand M, Ullrich V, et al: Spectral studies on structure-activity relationships of thromboxane synthase inhibitors. Eur J Biochem 157:217-223, 1986
9. 2-isoprostanes) in smokers. N Engl J Med 33:1198-1203, 1995
10. Reilly M, Delanty N, Lawson JA, et al: Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 94:19-25, 1996
11. Pilz H, Oguogho A, Chehne F, et al: Quitting cigarette smoking results in a fast improvement of in vivo oxidation injury (determined via plasma, serum and urinary isoprostanes). Thromb Res 99:209-221, 2000
12. Obata T, Tomaru K, Nagakura T, et al: Smoking and oxidant stress: Assay of isoprostane in human urine by gas chromatography-mass spectrometry. J Chromatogr B 746:11-15, 2000
13. Zhou JF, Yan XF, Guo FZ, et al: Effects of cigarette smoking and smoking cessation on plasma constituents and enzyme activities related to oxidative stress. Biomed Environ Sci 13:44-55, 2000
14. Chehne F, Oguogho A, Lupattelli G, et al: Increase of isoprostane 8-epi-PGF(2alpha) after restarting smoking. Prostaglandins Leukot Essent Fatty Acids 64:307-310, 2001
15. Pignatelli B, Li CO, Boffetta P, et al: Nitrated and oxidized plasma proteins in smokers and lung cancer patients. Cancer Res 61:778-784, 2001
16. MacMillan-Crow LA, Crow JP, Kerby JD, et al: Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts. Proc Natl Acad Sci U S A 93:11853-11858, 1996
17. Knight-Lozano CA, Young CG, Burow DL, et al: Cigarette smoke exposure and hypercholesterolemia increase mitochondrial damage in cardiovascular tissues. Circulation 105:849-854, 2002
18. Loft S, Poulsen HE: Cancer risk and oxidative DNA damage in man. J Mol Med 74:297, 1996
19. Howard DJ, Ota RB, Briggs LA, et al: Oxidative stress induced by environmental tobacco smoke in the workplace is mitigated by antioxidant supplementation. Cancer Epidemiol Biomarkers Prev 7:981-988, 1998
20. Lee SH, Blair IA: Analysis of etheno 2′-deoxyguanosine adducts as dosimeters of AKR-mediated oxidative stress, in Penning TM, Petrash JM (eds): Aldo-Keto Reductases and Toxicant Metabolism. Oxford, Oxford University Press, 2003
21. Antioxidant defences, in Halliwell B, Gutteridge JMC, eds. Free radicals in biology and medicine. Oxford: Oxford University Press, 1999, pp 105-245
22. Ghiselli A, Serafini M, Natella F, et al: Total antioxidant capacity as a tool to assess redox status: Critical view and experimental data. Free Radic Biol Med 29:1106-1114, 2000
23. Chisolm GM, Steinberg D: The oxidative modification hypothesis of atherogenesis: An overview. Free Radic Biol Med 28:1815-1826, 2000
24. 2 isoprostanes in hypercholesterolemia. Circulation 98:2822-2828, 1998
25. De Caterina R, Cipollone F, Filardo FP, et al: Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation in hypercholesterolemic subjects: No further effect of vitamin E. Circulation 106:2543-2549, 2002
26. Kagota S, Yamaguchi Y, Shinozuka K, et al: Cigarette smoke-modified low density lipoprotein impairs endothelium-dependent relaxation in isolated rabbit arteries. Gen Pharmacol 27:447-481, 1996
27. Gouaze V, Dousset N, Dousset JC, et al: Effect of nicotine and cotinine on the susceptibility to in vitro oxidation of LDL in healthy non smokers and smokers. Clin Chim Act 277:25-37, 1998
28. Scheffler E, Wiest E, Woehrle J, et al: Smoking influences the atherogenic potential of low density lipoprotein. Clin Invest 70:263-265, 1992
29. Siekmeier R, Wilifroth P, Wieland H, Groß W, et al: Lowe density lipoprotein susceptibility to in vitro oxidation in healthy smokers and non-smokers. Clin Chem 42:524-530, 1996
30. Princen HMG, Van Poppel G, Vogeizang C, et al: Supplementation with vitamin E but not β-carotene in vivo protects low density lipoproteins from lipid peroxidation in vitro. Arterioscler Thromb 12:554-562, 1992
31. Chen C, Lao G: Cigarette smoke inhibits oxidative modification of low density lipoprotein. Atherosclerosis 112:177-185, 1995
32. Harats D, Ben-Naim M, Dabach Y, et al: Cigarette smoking renders LDL susceptible to peroxidative modification and enhanced metabolism by macrophages. Atherosclerosis 79:245-252, 1989
33. Santanam N, Sanchez R, Hendler S, et al: Aqueous extracts of cigarette smoke promote the oxidation of low density lipoprotein by peroxidases. FEBS Lett 414:549-551, 1997
34. Sasaki A, Kondo K, Sakamoto Y, et al: Smoking cessation increases the resistance of low-density lipoprotein to oxidation. Atherosclerosis 130:109-111, 1997
35. Tsuchiya M, Asada A, Kasahara E, et al: Smoking a single cigarette rapidly reduces combined circulations of nitrate and nitrate and the concentrations of antioxidants in plasma. Circulation 105:1155-1157, 2002
36. Cai H, Harrison DG: Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ Res 87:840-844, 2000
37. Vassier-Taussat M, Camilli T, Aron Y, et al: Effects of tobacco smoke and benzo[a]pyrene on human endothelial cell and monocyte stress response. Am J Physiol 280:H1293-H1300, 2001
38. Kalra VK, Ying Y, Deemer K, et al: Mechanism of cigarette smoke condensate induced adhesion of human monocytes to cultured endothelial cells. J Cell Physiol 160:154-162, 1994
39. Weber C, Erl W, Weber K, et al: Increased adhesiveness of isolated monocytes to endothelium is prevented by vitamin C intake in smokers. Circulation 93:1448-1492, 1996
40. Lehr H-A, Frei B, Arfors KE: Vitamin C prevents cigarette smoke-induced leukocyte aggregation and adhesion to endothelium in vivo. Proc Natl Acad Sci USA 91:7688-7692, 1994
41. Bridges RB, Fu MC, Rehm SR: Increased neutrophil myeloperoxidase activity associated with cigarette smoking. Eur J Respir Dis 67:84-93, 1985
42. Kannel WB, McGee DL, Castelli WP: Latest perspectives on cigarette smoking and cardiovascular disease. J Card Rehab 4:267, 1984
43. Fuster V, Chesebro JH, Frye RL, et al: Platelet survival and the development of coronary artery disease in the young adult: Effects of cigarette smoking, strong family history and medical therapy. Circulation 63:546-551, 1981
44. 2 and prostacyclin during chronic smoking and withdrawal in man. Clin Res 33:521A, 1985
45. 2 and prostacyclin metabolites in young men. Circulation 83:1698-1704, 1991
46. Lassila R, Seyberth HW, Haapanen A, et al: Vasoactive and atherogenic effects for cigarette smoking: A study of monozygotic twins discordant for smoking. BMJ 297:955-960, 1998
47. Meade TW, Vickers MV, Thompson SG, et al: Epidemiological characteristics of platelet aggregability. BMJ 290:428-432, 1985
48. Freedman JE, Ting B, Hankin B, et al: Nitric oxide release from activated platelets inhibits platelet recruitment. J Clin Invest 100:350-356, 1997
49. Moncada S, Palmer RMJ, Higgs EA: Nitric oxide: Physiology, pathophysiology and pharmacology. Pharmacol Rev 43:109-142, 1991
50. Takajo Y, Ikeda H, Haramaki N, et al: Augmented oxidative stress of platelets in chronic smokers. J Am Coll Cardiol 38:1320-1327, 2001
51. Audoly LP, Rocca B, Fabre JE, et al: Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo. Circulation 101:2833-2840, 2000
52. Davi G, Ciabattoni G, Consoli A, et al: In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: Effects of improved metabolic control and vitamin E supplementation. Circulation 99:224-229, 1999
53. Mirshahi F, Vasse M, Vincent L, et al: Fibrinogen: A vascular risk factor, why? Contributing effect of oncostatin M on both fibrinogen biosynthesis by hepatocytes and participation in atherothrombotic risk related to modification of endothelial cells. Ann N Y Acad Sci 936:621-624, 2001
54. Wilhelmsen L, Svardsudd K, Korsan-Bengsten K, et al: Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 311:501-505, 1984
55. Stone MC, Thorp JM: Plasma fibrinogen - a major coronary risk factor. J R Coll Gen Pract 35:565-569, 1985
56. Tuut M, Hense H-W: Smoking, other risk factors and fibrinogen levels: Evidence of effect modification. Ann Epidemiol 11:232-238, 2001
57. Green TAE, Lamlum H, Humphries SE: The association of combined alpha and beta fibrinogen genotype on plasma fibrinogen levels in smokers and non-smokers. J Med Genet 32:585-589, 1995
58. Cooke DG, Cappuccio FP, Atkinson RW, et al: Ethnic differences in fibrinogen levels: The role of environmental factors and the β-fibrinogen gene. Am J Epidemiol 153:799-806, 2001
59. Gole MD, Souza JM, Choi I, et al: Plasma proteins modified by tyrosine nitration in acute respiratory syndrome. Am J Physiol 2278:L961-L967, 2000
60. Sambola A, Osende J, Hathcock J, et al: Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 107:973-977, 2003
61. Barua RS, Ambrose JA, Dhanonoy CS, et al: Smoking is associated with altered endothelial-derived fibrinolytic and antithrombotic factors. An in vitro demonstration. Circulation 106:905-908, 2002
62. Busacca M, Balconi G, Pietra A, et al: Maternal smoking and prostacyclin production by culture endothelial cells from umbilical arteries. Am J Obstet Gynecol 148:1127-1130, 1984
63. Matetzky S, Tani S, Kangavari S, et al: Smoking increases tissue factor expression in atherosclerotic plaques: Implications for plaque thrombogenicity. Circulation 102:602-604, 2000
64. Celermajer DS, Sorensen KE, Gooch VM, et al: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340:1111-1115, 1992
65. Furchgott RF, Zawadzki JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288:373-376, 1980
66. Schachinger V, Britten MB, Zeiber AM: Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101:1899-1906, 2000
67. Barua RS, Ambrose JA, Eales-Reynolds L-J, et al: Heavy and light cigarette smokers have similar dysfunction of endothelial regulatory activity. J Am Coll Cardiol 39:1758-1763, 2002
68. Celermajer DS, Sorensen KE, Georgakopoulos D, et al: Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 88:2149-2155, 1993 (abstr)
69. Celermajer DS, Adams MR, Clarkson P, et al: Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N Engl J Med 334:150-154, 1996
70. Lekakis J, Papamichael C, Vemmos C, et al: Effect of acute cigarette smoking on endothelium-dependent brachial artery dilatation in healthy individuals. Am J Cardiol 79:529-531, 1997
71. Zhang J, Ying X, Lu Q, et al: A single high dose of vitamin C counteracts the acute negative effect on microcirculation induced by smoking a cigarette. Microvasc Res 58:305-311, 1999
72. Motoyama T, Kawano H, Kugiyama K, et al: Endothelium-dependent vasodilation in the brachial artery is impaired in smokers: Effects of vitamin C. Am J Physiol 273:H1644-H1650, 1997
73. Heitzer T, Just H, Münzel T: Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation 94:6-9, 1996
74. Raitakari OT, Adams MR, McCredie RJ, et al: Oral vitamin C and endothelial function in smokers: Short-term improvement but no sustained beneficial effect. J Am Coll Cardiol 25:1616-1621, 2000
75. Heitzer T, Brockhoff C, Mayer B, et al: Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: Evidence for a dysfunctional nitric oxide synthase. Circ Res 86:e36-e41, 2000
76. He J, Vupputuri S, Allen K, et al: Passive smoking and the risk of coronary heart disease - a meta-analysis of epidemiologic studies. N Engl J Med 340:920-926, 1999
77. Glantz SA, Parmley WW: Even a little second hand smoke is dangerous. JAMA 286:462-463, 2001
78. Anonymous: Annual smoking attributable mortality, years of potential life lost and economic costs - United States 1995-1999. MMWR Morb Mortal Wkly Rep 51:300-303, 2002
79. Sumida H, Watanabe H, Kugiyama K, et al: Does passive smoking impair endothelium-dependent coronary artery dilation in women? J Am Coll Cardiol 31:811-815, 1998
80. Howard DJ, Ota RB, Briggs LA, et al: Environmental tobacco smoke in the workplace induces oxidative stress in employees, including increased production of 8-hydroxy-2′-deoxyguanosine. Cancer Epidemiol Biomarkers Prev 7:141-146, 2002
81. Visioli F, Galli C, Plasmati E, et al: Olive phenol hydroxytyrosol prevents passive smoking-induced oxidative stress. Circulation 102:2169-2171, 2000
82. Valkonen M, Kuusi T: Passive smoking induces atherogenic changes in low-density lipoprotein. Circulation 97:2012-2016, 2003
83. Lifrak P, Gariti P, Alterman AI, et al: Results of two levels of adjunctive treatment used with the nicotine patch. Am J Addict 6:93-98, 1997
84. Joseph AM, Norman SM, Ferry LH, et al: The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 335:1792-1798, 1996
85. Heeschen C, Jang JJ, Weis M, et al: Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med 7:833-839, 2001
86. Hill P, Haley NJ, Wynder EL: Cigarette smoking: Carboxyhemoglobin, plasma nicotine, cotinine and thiocyanate vs self-reported smoking data and cardiovascular disease. J Chronic Dis 36:439-449, 1983
87. Heeschen C, Weis M, Aicher A, et al: A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. J Clin Invest 110:527-536, 2002
88. Aicher A, Heeschen C, Mohaupt M, et al: Nicotine strongly activates dendritic cell-mediated adaptive immunity: Potential role for the progression of atherosclerotic lesions. Circulation 107:604-611, 2003
89. Wei W, Kim Y, Boudreau N: Association of smoking with serum and dietary levels of antioxidants in adults: NHANES III, 1988-1994. Am J Public Health 91:258-264, 2001
90. Ma J, Hampl JS, Betts NM: Antioxidant intakes and smoking status: Data from the continuing survey of food intakes by individuals 1994-1996. Am J Clin Nutr 71:774-780, 2000
91. Walmsey CM, Bates CJ, Cole TJ: Relationship between cigarette smoking and nutrient intakes and blood status of older people living in the UK: Further analysis of data from the National Diet and Nutrition Survey of people aged 65 years and over, 1994/95. Public Health Nutr 2:199-208, 2003
92. D'Avanzo B, La Vecchia C, Braga C, et al: Nutrient intake according to education, smoking and alcohol in Italian women. Nutr Cancer 28:46-51, 1997
93. Panda K, Chattopadhyay R, Ghosh MK, et al: Vitamin C prevents cigarette smoke induced oxidative damage of proteins and increased proteolysis. Free Radic Biol Med 27:1064-1079, 1999
94. Panda K, Chattopadhyay R, Chattopadhyay DJ, et al: Vitamin C prevents cigarette smoke-induced oxidative damage in vivo. Free Radic Biol Med 29:115-124, 2000
95. Neunteufl T, Priglinger U, Heher S, et al: Effects of vitamin E on chronic and acute endothelial dysfunction. J Am Coll Cardiol 35:277-283, 2000
96. Mulholland CW, Strain JJ, Trinick TR: Serum antioxidant potential, and lipoprotein oxidation in female smokers following vitamin C supplementation. Int J Food Sci Nutr 47:227-231, 1996
97. van Tits LJ, de Waart F, Hak-Lemmers HL, et al: Effects of alpha-tocopherol on superoxide production and plasma intercellular adhesion molecule-1 and antibodies to oxidized LDL in chronic smokers. Free Radic Biol Med 30:1122-1129, 2001
98. Brown KM, Morrice PC, Duthie GG: Vitamin E supplementation suppresses indices of lipid peroxidation and platelet changes in blood of smokers and nonsmokers but plasma lipoprotein concentrations remain unchanged. Am J Clin Nutr 60:383-387, 1994
99. Habib MP, Tank LJ, Lane LC, et al: Effect of vitamin E on exhaled ethane in cigarette smokers. Chest 11:684-690, 1999
100. Jialal I, Devaraj S: Antioxidants and atherosclerosis: Don't throw out the baby with the bath water. Circulation 107:926-928, 2003
101. Meagher EA, Barry OP, Lawson JA, et al: Effects of Vitamin E on lipid peroxidation in healthy volunteers. JAMA 285:1178-1182, 2001
102. 2-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. Circulation 102:539-545, 2000
103. 2-isoprostanes in plasma of smokers. Cancer Epidemiol Biomarkers Prev 11:7-13, 2002
104. Heitzer T, Herttuala SY, Wild E, et al: Effect of vitamin E on endothelial vasodilator function in patients with hypercholesterolemia, chronic smoking or both. J Am Coll Cardiol 33:499-505, 1999
105. Porkkala-Sarataho EK, Jukka T, Nyyssonen MK, et al: Long-term effects of vitamin E, vitamin C, and combination supplementation on urinary 7-hydro-8-oxo-2′-deoxyguanosine, serum cholesterol oxidation products, and oxidation resistance of lipids in nondepleted men. Arterioscler Thromb Vasc Biol 20:2087-2093, 2000
106. Traber MG, Winklhofer-Roob BM, Roob JM, et al: Vitamin E kinetics in smokers and nonsmokers. Free Radic Biol Med 31:1368-1374, 2001
107. Jacobson JS, Begg MD, Wang LW, et al: Effects of a 6-month vitamin intervention of DNA damage in heavy smokers. Cancer Epidemiol Biomarkers Prev 9:1303-1311, 2000
108. Fuller CJ, May MA, Martin KJ: The effect of vitamin E and vitamin C supplementation of LDL oxidisability and neutrophil respiratory burst in young smokers. J Am Coll Nutr 19:361-369, 2000
109. Aghdassi E, Royall D, Allard JP: Oxidative stress in smokers supplemented with vitamin C. Int J Vitam Nutr Res 69:45-51, 1999
110. Porkkala-Sarataho EK, Nyyssonen MK, Kaikkonen JE, et al: A randomised, single-blind, placebo-controlled trial of the effects of 200mg alpha-tocopherol on the oxidation resistance of atherogenic lipoproteins. Am J Clin Nutr 68:1034-1041, 1998
111. Rapola JM, Virtamo J, Ripatti S, et al: Effects of alpha tocopherol and beta carotene supplements on symptoms, progression and prognosis of angina pectoris. Heart 79:454-458, 1998
112. Teikari JM, Laatikainen L, Rapola JM, et al: Retinal vascular changes following supplementation with alpha-tocopherol or beta-carotene. Acta Ophthalmol Scand 76:68-73, 1998
113. Samman S, Brown AJ, Beltran C, et al: The effect of ascorbic acid on plasma lipids and oxidisability of LDL in male smokers. Eur J Clin Nutr 51:472-477, 1997
114. Rapola JM, Virtamo J, Ripatti S, et al: Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarctions. Lancet 349:1715-1720, 1997
115. Nyyssonen MK, Poulsen HE, Hayn EM, et al: Effect of supplementation of smoking men with plain or slow release ascorbic acid on lipoprotein oxidation. Eur J Clin Nutr 51:154-163, 1997
116. Prieme H, Loft S, Nyyssonen MK, et al: No effect of supplementation with vitamin E, ascorbic acid, or coenzyme Q10 on oxidative damage DNA damage estimated by 8-oxo-7,8-dihydro-2′-deoxyguanosine excretion in smokers. Am J Clin Nutr 65:503-507, 1997
117. Porkkala-Sarataho EK, Nyyssonen MK, Salonen JT: Increased oxidation resistance of atherogenic plasma lipoproteins at high vitamin E levels in non-vitamin E supplemented men. Atherosclerosis 124:83-94, 1996
118. Rapola JM, Virtamo J, Haukka JK, et al: Effect of vitamin E and beta carotene on the incidence of angina pectoris: A randomised double-blind, controlled trial. JAMA 275:693-698, 1996
119. Theron AJ, Anderson R: Investigation of the effects of oral administration of ascorbate on the functional activity of serum alpha-1-protease inhibitor and oxidant release by blood phagocytes trom cigarette smokers in a placebo-controlled, double blind crossover trial. Int J Vitam Nutr Res 58:218-224, 1988
120. Leppala JM, Virtamo J, Fogelholm R, et al: Controlled trial of α-tocopherol and β-carotene supplements on stroke incidence and mortality in male smokers. Arterioscler Thromb Vasc Biol 20:230-237, 2000
121. Nyyssonen MK, Porkkala E, Salonen R, et al: Increase in oxidation resistance of atherogenic serum lipoproteins following antioxidant supplementation: A randomised double-blind placebo-controlled clinical trial. Eur J Clin Nutr 48:633-642, 1994